Offshoring clinical trials to emerging markets around the world is receiving increasing attention as a very attractive alternative in the clinical development process. This follows as a natural reaction to already successful offshoring activities in the IT industry. The big question is: Do clinical research capabilities comparable to the US in terms of sophistication and FDA-compliance exist anywhere else in the world? And if they do, are they ready to handle the huge surge in business likely headed their way?
Outsourcing Clinical Trials: A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness Index analyzes the key drivers that have made the search for effective clinical trial outsourcing a necessity rather than an option in today’s drug development efforts. The current climate of clinical trials in emerging markets across the world is examined. Geographic areas covered include Central and Eastern Europe, Latin America, Australia and New Zealand, Africa, Asia and India.
The report also includes the Clinical Trial Outsourcing Global Attractiveness Index. This vital piece of original research includes tables and graphs which rank international locations, according to the following criteria:
Study Cost Indicators Patient Indicators Disease Indicators Clinical Research Indicators Research Personnel Indicators Study Site Indicators Business Environment Indicators The index serves as an invaluable starting resource for pharmaceutical companies seeking to outsource their clinical trial functions to international destinations.
Each region covered in this report includes the following sub-sections, which break down, in depth, the factors vital to an understanding of international clinical trial outsourcing destinations:
Location Target Population Alternative Medicine Disease Demographics Study Investigator Profile Study Site Characteristics Regulatory Climate Study Costs Clinical Trial Activity Pharmaceutical Market Key Market Advantages/Strengths Key Market Disadvantages/Weaknesses Report Recommendations Reasons to buy this report:
Focused only on outsourcing of clinical trials - This is the primary short-term focus of Pharma companies in developed nations. Content is not diluted by an excessive discussion of US-based clinical trials or US-based CROs or by too broad an analysis of overall pharma outsourcing Provides in depth analysis as to why particular regions are becoming preferred destinations for Pharma outsourcing in general and clinical trials in particular Provides objective comparative analysis of regions/countries and their potential as clinical trial destinations. This analysis assesses individual destination strengths with regard to scientific merit, technical capability, manpower, facilities, etc. Prepared by an experienced team of authors who have a deep understanding of industry dynamics and also have innumerable sources within the pharma industry to help the reader gain the "insider" advantage
